Skip to main content
SpringerLink
Log in

Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Class III antiarrhythmic drugs, especially amiodarone (a broad-spectrum antiarrhythmic agent), have gained popularity for use in clinical practice in recent years. Other class III antiarrhythmic drugs include bretylium, dofetilide, ibutilide and sotalol. These agents are effective for the management of various types of cardiac arrhythmias both atrial and ventricular in origin.

Class III antiarrhythmic drugs may interact with other drugs by two major processes: pharmacodynamic and pharmacokinetic interactions. The pharmacodynamic interaction occurs when the pharmacological effects of the object drug are stimulated or inhibited by the precipitant drug. Pharmacokinetic interactions can result from the interference of drug absorption, metabolism and/or elimination of the object drug by the precipitant drug.

Among the class III antiarrhythmic drugs, amiodarone has been reported to be involved in a significant number of drug interactions. It is mainly metabolised by cytochrome P450 (CYP)3A4 and it is a potent inhibitor of CYP1A2, 2C9, 2D6 and 3A4. In addition, amiodarone may interact with other drugs (such as digoxin) via the inhibition of the P-glycoprotein membrane transporter system, a recently described pharmacokinetic mechanism of drug interactions.

Bretylium is not metabolised; it is excreted unchanged in the urine. Therefore the interactions between bretylium and other drugs (including other antiarrhythmic drugs) is primarily through the pharmacodynamic mechanism.

Dofetilide is metabolised by CYP3A4 and excreted by the renal cation transport system. Drugs that inhibit CYP3A4 (such as erythromycin) and/or the renal transport system (such as triamterene) may interact with dofetilide.

It appears that the potential for pharmacokinetic interactions between ibutilide and other drugs is low. This is because ibutilide is not metabolised by CYP3A4 or CYP2D6. However, ibutilide may significantly interact with other drugs by a pharmacodynamic mechanism.

Sotalol is primarily excreted unchanged in the urine. The potential for drug interactions due to hepatic enzyme induction or inhibition appears to be less likely. However, a number of drugs (such as digoxin) have been reported to interact with sotalol pharmacodynamically.

If concurrent use of a class III antiarrhythmic agent and another drug cannot be avoided or no published studies for that particular drug interaction are available, caution should be exercised and close monitoring of the patient should be performed in order to avoid or minimise the risks associated with a possible adverse drug interaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129–47

    PubMed  CAS  Google Scholar 

  2. Tatro DS, editor. Drug interaction facts. St Louis: Facts and Comparisons: A Wolters Kluwer Company, 2002

    Google Scholar 

  3. Blaufarb I, Pfeifer TM, Frishman WH. Beta-blockers drug interactions of clinical significance. Drug Saf 1995; 13(6): 359–70

    Article  PubMed  CAS  Google Scholar 

  4. Rosenthal T, Ezra D. Calcium antagonists: drug interactions of clinical significance. Drug Saf 1995; 13(3): 157–87

    Article  PubMed  CAS  Google Scholar 

  5. Rees A, Dalal JJ, Reid PG, et al. Dangers of amiodarone and anticoagulant treatment. BMJ 1981; 282: 1756–7

    Article  PubMed  CAS  Google Scholar 

  6. Martinowitz U, Robinovich J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med 1981; 304: 671–2

    Article  PubMed  CAS  Google Scholar 

  7. Singhvi SM, Duchin KL, Willard DA, et al. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 1982; 32: 182–9

    Article  CAS  Google Scholar 

  8. Drummer OH, Thompsom J, Hooper R, et al. Effect of probenecid on the disposition of captopril and captopril dimer in the rat. Biochem Pharmacol 1985; 34: 3347–51

    Article  PubMed  CAS  Google Scholar 

  9. Tatro DS. Drug interactions. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford: Appleton and Lange, 1999: 35–49

    Google Scholar 

  10. Stockley IH. General considerations and an outline survey of some basic interaction mechanisms. In: Stockley IH, editor. Drug interactions. 4th edition. London: The Pharmaceutical Press, 1996: 1–15

    Google Scholar 

  11. Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmcol 2000; 41: 715–22

    Article  Google Scholar 

  12. Rieder MJ, Spino M. The theophylline-erythromycin interaction. J Asthma 1988; 25: 195–204

    Article  PubMed  CAS  Google Scholar 

  13. Matheny CJ, Lamb MW, Brouwer KLR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778–96

    Article  PubMed  CAS  Google Scholar 

  14. Hunter J, Hirst BH. Intestinal secretion of drugs: the role of Pglycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Del 1997; 25: 129–57

    Article  CAS  Google Scholar 

  15. Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430–6

    Article  PubMed  CAS  Google Scholar 

  16. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610–7

    Article  PubMed  CAS  Google Scholar 

  17. Schrager LK, D’Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280: 67–71

    Article  PubMed  CAS  Google Scholar 

  18. Hutchison TA, Shahan DR, Anderson ML, editors. Drugdex system. Greenwood Village (CO): Micromedex Inc.

  19. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43: 69–110

    Article  PubMed  CAS  Google Scholar 

  20. Brendorp B, Pedersen O, Torp-Pedersen C, et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 2002; 25(12): 847–65

    Article  PubMed  CAS  Google Scholar 

  21. Naccarelli GV, Wolbrette DL, Dell’Orfano JT, et al. Amiodarone: what we have learned from clinical trials? Clin Cardiol 2000; 23: 73–82

    Article  PubMed  CAS  Google Scholar 

  22. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84–112

    PubMed  CAS  Google Scholar 

  23. Leor J, Levartowsky D, Sharon C, et al. Amiodarone and betaadrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J 1988; 116: 206–7

    Article  PubMed  CAS  Google Scholar 

  24. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99: 2268–75

    Article  PubMed  CAS  Google Scholar 

  25. Nitsch J, Luderitz B. Acceleration of amiodarone elimination by cholestyramine. Dtsch Med Wochenschr 1986; 111: 1241–4

    Article  PubMed  CAS  Google Scholar 

  26. Lee TH, Friedman PL, Goldman L, et al. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. Am Heart J 1985; 109: 163–4

    Article  PubMed  CAS  Google Scholar 

  27. Lubic SP, Nguyen KPV, Dave B, et al. Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J Cardiovas Pharmacol 1994; 24: 707–14

    Article  CAS  Google Scholar 

  28. Wagner JA, Weisman HF, Levine JH, et al. Differential effects of amiodarone and desmethylamiodarone on calcium antagonist receptors. J Cardiovasc Pharmacol 1990; 15: 501–7

    Article  PubMed  CAS  Google Scholar 

  29. Product Information. Propulsid® cisapride. Titusville (NJ): Janssen Pharmaceutica Inc., 2000

  30. Nattel S, Singh BN. Evolution, mechanism, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999; 84: 11R–9R

    Article  PubMed  CAS  Google Scholar 

  31. Nicolau D, Uber W, Crumbley III AJ, et al. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992; 11: 564–8

    PubMed  CAS  Google Scholar 

  32. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840–7

    Article  PubMed  CAS  Google Scholar 

  33. Klein HO, Beker B, DiSegni E, et al. Asystole produced by the combination of amiodarone and digoxin. Am Heart J 1987; 113: 399–400

    Article  PubMed  CAS  Google Scholar 

  34. Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111–6

    Article  PubMed  CAS  Google Scholar 

  35. Maragno I, Santostasi G, Gaion RM, et al. Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. Int J Clin Pharm Res 1984; 4: 149–53

    CAS  Google Scholar 

  36. Santostasi G, Fantin M, Maragno I, et al. Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects. J Cardiovasc Pharmacol 1987; 9: 385–90

    Article  PubMed  CAS  Google Scholar 

  37. Henderson RP, Solomon CP. Use of cholestyramine in the treatment of digoxin intoxication. Arch Intern Med 1988; 148: 745–6

    Article  PubMed  CAS  Google Scholar 

  38. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161–6

    PubMed  CAS  Google Scholar 

  39. Nolan Jr PE, Marcus FI, Hoyer GL, et al. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther 1989; 46: 43–50

    Article  PubMed  CAS  Google Scholar 

  40. McGovern B, Geer VR, LaRaia PJ, et al. Possible interaction between amiodarone and phenytoin. Ann Intern Med 1984; 101: 650–1

    PubMed  CAS  Google Scholar 

  41. Nolan Jr PE, Marcus FI, Karol MD, et al. Effect of phenytoin on the clinical pharmacokinetics of amiodarone. J Clin Pharmacol 1990; 30: 1112–9

    PubMed  Google Scholar 

  42. Product Information. Tikosyn [(TM)] dofetilide. New York (NY): Pfizer Inc., 1999

  43. Product Information. Tambocor [(TM)] flecainide acetate. St Paul (MN): 3M Pharmaceuticals, 1997

  44. Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55: 256–69

    Article  PubMed  CAS  Google Scholar 

  45. Product Information. Corvert® ibutilide fumarate injection. Kalamazoo (MI): Upjohn Company, 1998

  46. Keidar S, Grenadier E, Palant A. Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration. Am Heart J 1982; 104: 1384–5

    Article  PubMed  CAS  Google Scholar 

  47. Siegmund J, Wilson J, Imhoff T. Amiodarone interaction with lidocaine. J Cardiovasc Pharmacol 1993; 21: 513–5

    Article  PubMed  CAS  Google Scholar 

  48. Marcus FI. Drug interactions with amiodarone. Am Heart J 1983; 106: 924–30

    Article  PubMed  CAS  Google Scholar 

  49. Windle J, Prystowsky EN, Miles WM, et al. Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther 1987; 41: 603–10

    Article  PubMed  CAS  Google Scholar 

  50. Product Information. Betapace AF[(TM)] sotalol hydrochloride. Wayne, (NJ): Berlex Laboratories, 2000

  51. Product Information. Agenerase® amprenavir. Triangle Park (NC), Glaxo Wellcome Inc. Research, 2000

  52. Product Information. Viracept® nelfinavir mesylate. La Jolla (CA): Agouron Pharmaceuticals Inc., 1999

  53. Product Information. Norvir® ritonavir. North Chicago (IL): Abbott Laboratories, 1999

  54. Lohman JJ, Reichert LJ, Degen LP. Antiretroviral therapy increases serum concentrations of amiodarone [letter]. Ann Pharmacother 1999; 33: 645–6

    Article  PubMed  CAS  Google Scholar 

  55. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988; 148: 1779–81

    Article  PubMed  CAS  Google Scholar 

  56. Rotmensch HH, Belhassen B Amiodarone in the management of cardiac arrhythmias: current concepts. Med Clin North Am 1988; 72: 321–58

    PubMed  CAS  Google Scholar 

  57. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose- and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985; 28: 257–61

    Article  PubMed  CAS  Google Scholar 

  58. Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58: 43–51

    PubMed  CAS  Google Scholar 

  59. Richard C, Riou B, Berdeaux A, et al. Prospective study of the potentiation of acenocoumarol by amiodarone. Eur J Clin Pharmacol 1985; 28: 625–9

    Article  PubMed  CAS  Google Scholar 

  60. Product Information. Tequin® gatifloxacin. Princeton (NJ): Bristol-Myers Squibb Company, (PI revised 2000 Aug) reviewed 2001 Jan

  61. Product Information. Avelox™ moxifloxacin hydrochloride. West Haven (CT): Bayer Corporation, (PI revised 2000 Nov) reviewed 2001 Mar

  62. Product Information. Zagam® sparfloxacin. Collegeville (PA): Rhone-Poulenc Rorer Pharmaceuticals Inc., (PI revised 1998 Oct) reviewed 2001 May

  63. Product Information. Anzemet® dolasetron. Kansas City (MO): Hoechst Marion Roussel Inc., 1997

  64. Product Information. Orap® pimozide. Sellersville (PA): Gate Pharmaceuticals, 1999

  65. Tsikouris JP, Cox CD. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy 2001; 21: 1514–29

    Article  PubMed  CAS  Google Scholar 

  66. Efacts CD-ROM for Windows. St Louis (MO): Facts and comparisons; 2002 Oct

  67. Chandrasekaran S, Steinberg JS. Efficacy of bretylium tosylate for ventricular tachycardia. Am J Cardiol 1999; 83: 115–7, A9

    Article  PubMed  CAS  Google Scholar 

  68. Thomas M, Maconochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 1996; 41: 77–81

    Article  PubMed  CAS  Google Scholar 

  69. Product Information. Geodon® ziprasidone. New York (NY): Pfizer Inc., 2001

  70. Auer J, Berent R, Weber T, et al. Current and new drugs for the treatment of arrhythmias. Curr Opin Investig Drugs 2002; 3: 1029–36

    PubMed  CAS  Google Scholar 

  71. Matyus P, Varro A, Papp JG, et al. Antiarrhythmic agents: current status and perspectives. Med Res Rev 1997; 17: 427–51

    Article  PubMed  CAS  Google Scholar 

  72. Abel S, Nichols DJ, Brearley CJ, et al. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 2000; 49: 64–71

    Article  PubMed  CAS  Google Scholar 

  73. Elliott HL, McLean K, Sumner DJ, et al. Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers. Clin Pharmacol Ther 1981; 29: 303–9

    Article  PubMed  CAS  Google Scholar 

  74. Seideman P, Grahnen A, Haglund K, et al. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 1982; 13: 865–70

    Article  PubMed  CAS  Google Scholar 

  75. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol 1997; 43: 269–72

    Article  PubMed  CAS  Google Scholar 

  76. Warren R, Vohra J, Hunt D, et al. Serious interactions of sotalol with amiodarone and flecainide [letter]. Med J Aust 1990; 152: 277

    PubMed  CAS  Google Scholar 

  77. Price JF, Kertesz NJ, Snyder CS, et al. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age. Am Coll Cardiol 2002; 39: 517–20

    Article  CAS  Google Scholar 

  78. Saarimaa H. Combination of clonidine and sotalol in hypertension. BMJ 1976; 1(6013): 810

    Article  PubMed  CAS  Google Scholar 

  79. Bailey RR, Neale TJ. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. BMJ 1976; 1: 942–3

    Article  PubMed  CAS  Google Scholar 

  80. Singh S, Saini RK, DiMarco J, et al. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol 1991; 68: 1227–30

    Article  PubMed  CAS  Google Scholar 

  81. Skehan JD, Barnes JN, Drew PJ, et al. Hypokalaemia induced by a combination of a beta-blocker and a thiazide. BMJ 1982; 284: 83

    Article  PubMed  CAS  Google Scholar 

  82. McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 1984; 51: 157–62

    Article  PubMed  CAS  Google Scholar 

  83. Tian R, Koyabu N, Takanaga H, et al. Effect of grapefruit juice and orange on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The assistance of Joseph M. Scavone, Pharm D, Neil E. Henann, Pharm D and Dick A. Lauer, BBA in reviewing this manuscript is acknowledged.

No sources of funding were used to assist in the preparation of this manuscript.

The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Wyoming, and Pharmacy Services, Cheyenne VAMC, 2360 E. Pershing Blvd., Cheyenne, Wyoming, 82001, USA

    Weeranuj Yamreudeewong

  2. School of Pharmacy, University of Wyoming, Casper, Wyoming, USA

    Michael DeBisschop

  3. School of Pharmacy, University of Wyoming, Laramie, Wyoming, USA

    Linda G. Martin

  4. Cheyenne VAMC, Medicine Service, Cheyenne, Wyoming, USA

    Dennis L. Lower

Authors
  1. Weeranuj Yamreudeewong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael DeBisschop
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda G. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dennis L. Lower
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weeranuj Yamreudeewong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamreudeewong, W., DeBisschop, M., Martin, L.G. et al. Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs. Drug-Safety 26, 421–438 (2003). https://doi.org/10.2165/00002018-200326060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200326060-00004

Keywords

Search

Navigation